| Bioactivity | Eticlopride, a potent and selective D2 receptor antagonist, was investigated in rats with extensive dopamine denervation induced by 6-hydroxydopamine. Daily injections of eticlopride over 21 days increased D2 receptor density in intact brain regions but did not further augment already increased densities in denervated areas. Despite receptor density changes, functional sensitivity remained evident, as shown by contralateral rotations induced by D2 agonist quinpirole during wash-out periods. The study suggests that chronic D2 receptor blockade and dopamine denervation may share a common mechanism in upregulating D2 receptor density, contrary to previous reports suggesting additive effects of denervation and antagonist treatment[1]. |
| CAS | 84226-12-0 |
| Formula | C17H25ClN2O3 |
| Molar Mass | 340.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Eticlopride
CAS: 84226-12-0 F: C17H25ClN2O3 W: 340.85
Eticlopride, a potent and selective D2 receptor antagonist, was investigated in rats with extensive dopamine denervation
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.